661 abstracts found.



Results filter

Intra-operative Electron beam radiotherapy for advanced and recurrent abdominopelvic malignancies in the UK: Development, implementation, and medium term results

Year:

Session type:

Alex Mirnezami1
1University of Southampton

Surgery-dependent Translational Research

Year:

Session type:

Richard Shaw1
1NIHR Cancer Research Network (NCRN)

Lung Cancer IO – hi ho

Year:

Session type:

Mary O'Brien1
1Royal Marsden NHS Hospital

Challenges in Managing the Immune Related Toxicities of Cancer Immunotherapy

Year:

Session type:

Paul Nathan1
1Mount Vernon Hospital

Surviving the Cure: Blood and Marrow Transplantation as Model For Cancer Survivorship

Year:

Session type:

Navneet Majhail1
1Cleveland Clinic

The psychological impact of being on a monitoring pathway for early stage prostate cancer: a UK-wide mixed methods study.

Year:

Session type:

Eila Watson1,Lauren Matheson1,Sarah Wilding2,Johanna Nayoan3,Amy Downing2,Carol Rivas3,Jo Brett1,Penny Wright2,Therese Kearney4,William Cross5,Anna Gavin4,Adam Glaser2,Richard Wagland6
1Oxford Brookes University,2University of Leeds,3University College London,4Queens University Belfast,5Leeds Teaching Hospitals NHS Trust,6University of Southampton

Identification of novel therapeutic targets for triple negative breast cancer through integrative kinomics

Year:

Session type:

Roger Daly1
1Department of Biochemistry and Molecular Biology, Monash University

Pancreatic Cancer Immunotherapy: From Bench to Bedside

Year:

Session type:

George Miller1
1New York University School of Medicine

Heterocellular interactions in the tumour microenvironment

Year:

Session type:

Claus Jorgensen1
1CRUK Manchester Institute

Comparison of an oral factor Xa inhibitor with low molecular weight heparin in cancer patients with venous thromboembolism: results of the randomised select-d trial

Year:

Session type:

Annie Young1,Andrea Marshall2,Jenny Thirlwall2,Oliver Chapman3,Anand Lokare4,Catherine Hill2,Danielle Hale2,Janet Dunn2,Karen French3,Veronica Wilkie5,Gary H. Lyman6,Charles Hutchinson7,Peter MacCallum8,Ajay Kakkar9,FD Richard Hobbs10,Stavros Petrou2,Christopher J Poole3,Anthony Maraveyas11,Mark Levine12
1,2Warwick Clinical Trials Unit,3University Hospitals Coventry and Warwickshire,4Heart of England NHS Foundation Trust,5University of Worcester,6Fred Hutchinson Cancer Research Center,7Warwick Medical School,8Queen Mary University of London,9Thrombosis Research Institute,10Nuffield Department of Primary Care Health Sciences,11Hull York Medical School,12McMaster University

Tackling EArly Morbidity and Mortality in Myeloma (TEAMM): assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections in 977 patients

Year:

Session type:

Mark Drayson1,Stella Bowcock2,Tim Planche3,Gulnaz Iqbal4,Kerry Raynes5,Guy Pratt1,Kwee Yong6,Peter Hawkey1,Helen Higgins4,Jill Wood4,Janet Dunn4
1University of Birmingham,2King’s College NHS Trust,3St George's University Hospitals NHS Trust,4University of Warwick,5Cambridge University Hospitals,6UCL Cancer Institute

Results of POUT – A phase III randomised trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC)

Year:

Session type:

Alison Birtle1,Mark Johnson2,Roger Kockelbergh3,Francis Keeley, Jr.4,James Catto5,Rik Bryan6,Rob Jones7,John Chester8,David Dolling9,Jenny Donovan10,Ann French11,Chris Harris12,Thomas Powles13,Rachel Todd9,Lucy Tregellas9,Caroline Wilson10,Andrew Winterbottom14,Rebecca Lewis9,Emma Hall9
1Lancashire Teaching Hospitals NHS Foundation Trust,2Newcastle upon Tyne Hospitals NHS Trust,3University Hospitals Leicester,4North Bristol NHS Trust,5The University of Sheffield,6University of Birmingham,7Beatson West of Scotland Cancer Centre,8Cardiff University/Velindre Cancer Centre,9ICR-CTSU,10University of Bristol,11Southend University Hospital NHS,12Consumer Representative,13St Barts & the London NHS Trust,14Consumer representative/ Fight Bladder Cancer

Chromosome breakage and inheritable cancers

Year:

Session type:

Stephen West1
1The Francis Crick Institute

Cell function and tumor formation

Year:

Session type:

Stefano Piccolo1
1University of Padua

Inflammation driven cancer: Genes, cells and microbes

Year:

Session type:

Fiona Powrie1
1Kennedy Institute of Rheumatology, University of Oxford

Evolutionary dynamics of cancer subclones

Year:

Session type:

Trevor Graham1
1Barts Cancer Institute

Targeting the DNA Damage Response with a Selective CHK1 Inhibitor

Year:

Session type:

Ian Collins1
1The Institute of Cancer Research

Discovery of first-in class, selective and noncovalent small molecule inhibitors of DNMT1

Year:

Session type:

Allan Jordan1
1CRUK Manchester Institute

Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial

Year:

Session type:

Richard Martin1
1University of Bristol

Methodological issues in precision oncology trials

Year:

Session type:

Lucinda Billingham1
1Cancer Research UK Clinical Trials Unit, University of Birmingham

Computational Pathology: Challenges and Opportunities

Year:

Session type:

Nasir Rajpoot1
1University of Warwick

A novel application of two-step Mendelian randomization: applying the results of small feasibility studies of interventions to infer causal effects on clinical endpoints

Year:

Session type:

Meda R. Sandu1,Rhona Beynon1,Rebecca Richmond1,Diana L. Santos Ferreira1,J Athene Lane1,Richard M. Martin1
1University of Bristol

Digital Pathology & Artificial Intelligence, the Third Revolution in Pathology

Year:

Session type:

Manuel Salto-Tellez1
1Queen's University Belfast

Patient-reported outcomes in men with advanced and localised disease: Results from the UK-wide Life After Prostate Cancer Diagnosis study

Year:

Session type:

Amy Downing1,Penny Wright1,Sarah Wilding1,David Donnelly2,Luke Hounsome3,Eila Watson4,Richard Wagland5,Hugh Butcher1,Paul Kind1,Peter Selby1,James Catto6,William Cross7,Dyfed Huws8,David Brewster9,Anna Gavin2,Adam Glaser1
1University of Leeds,2Queens University Belfast,3Public Health England,4Oxford Brookes University,5University of Southampton,6University of Sheffield,7Leeds Teaching Hospitals NHS Trust,8Public Health Wales,9University of Edinburgh

Investigating the role of dysregulated RNA splicing in colorectal cancer initiation and progression

Year:

Session type:

Adam Hall1,Kevin Myant1
1Institute of Genetics and Molecular Medicine, The University of Edinburgh

Amino acid transporter SLC7A5 is required for growth of Kras-mutant colorectal cancer in vivo

Year:

Session type:

Arafath Najumudeen1,Fatih Ceteci1,Owen Sansom1
1Beatson Institute for Cancer Research

Inhibition of the pro-tumorigenic effects of TGFbeta in tumor therapy

Year:

Session type:

Carl-Henrik Heldin1
1Uppsala University

Deregulated TGF-β signalling in cancer

Year:

Session type:

Caroline Hill1
1The Francis Crick Institute

Role of TGF-beta in glioblastoma

Year:

Session type:

Joan Seoane1
1Vall d'Hebron University Hospital

Role of the gut microbiome in causing, detecting and treating coloretal cancer.

Year:

Session type:

Paul O'Toole1
1School of Microbiology and APC Microbiome Inst

Impact of patient’s gut microbiome on clinical reponse to cancer immunotherapy

Year:

Session type:

Robert Jenq1
1University of Texas MD Anderson Cancer Center

The burden of cancer due to inequalities and its likely causes – Introduction

Year:

Session type:

Yoryos Lyratzopoulos1
1University College London

Learning from research on cancer disparities in the US

Year:

Session type:

Nancy Keating1
1Harvard Medical School

Social inequalities in cancer screening participation

Year:

Session type:

Jo Waller1
1University College London

The role of individual and system factors on inequalities in cancer care and outcomes

Year:

Session type:

Bernard Rachet1
1London School of Hygiene and Tropical Medicine

Tumour microenvironment and radiation – friend or foe?

Year:

Session type:

Kaye Williams1
1University of Manchester

DNA damage repair inhibitors and radiation- are normal tissues spared?

Year:

Session type:

Susan Short1
1University of Leeds

The challenges of rare cancer: Time for change

Year:

Session type:

Richard Adams1
1Cardiff University

Designing trials in smaller populations

Year:

Session type:

Matthew Sydes1
1MRC Clinical Trials Unit at UCL

Core Outcomes Sets for trials and Core Information Sets for consultations: keeping them patient centred

Year:

Session type:

Jane Blazeby1,Angus McNair1
1University of Bristol

Best practices for integration of Patient-Reported Outcomes (PROs) into trials

Year:

Session type:

Derek Kyte1
1University of Birmingham

A Living Biobank Of Ovarian Cancer Ex Vivo Models Reveals Profound Mitotic Heterogeneity

Year:

Session type:

Stephen Taylor1
1University of Manchester

Efficacy of Nurse-Led Clinic in Managing Patients with Cancer

Year:

Session type:

Cyper Allan1
1University of Sheffield

The identification of a brown fat phenotype in colorectal cancer and its association with prognosis

Year:

Session type:

Graeme Murray1,Abdo Alnabulsi2,Beatriz Cash3,Ayham Alnabulsi3
1University of Aberdeen,2,3Vertebrate Antibodies

Pharmacophore-Based Virtual Screening for Identification of Human Helicase DDX3 Inhibitors

Year:

Session type:

Shailima Rampogu1,Ayoung Baek1,Minky Son1,Chanin Park1,Amir Zeb1,Keun Woo Lee1
1Gyeongsang National University

Magnetic resonance imaging in accurate TNM staging of rectal cancer – can we live up to the Royal Marsden standard?

Year:

Session type:

Nsiah Yvonne1,Ahmad Zia2,Philip Garwood2,Amdad Ahmed2,Brendan McIlroy2,Edmund Leung2
1West Midlands Deanery,2Hereford County Hospital

Phenome-wide association study of pancreatic cancer using summary genetic data

Year:

Session type:

Ryan Langdon1,Rebecca Richmond1,Gibran Hemani1,Jie Zheng1,Kaitlin Wade1,Robert Carreras2,Mattias Johansson2,Paul Brennan2,George Davey-Smith1,Caroline Relton1,Richard Martin1,Emma Vincent1,Philip Haycock1
1University of Bristol,2IARC

Acid ceramidase expression and poor neoadjuvant responses in rectal cancer – is the modulation of apoptosis a key mechanism?

Year:

Session type:

Narendranath Govindarajah1,Rachael Clifford1,Paul Sutton1,David Bowden1,Dale Vimalachandran2,Jason L Parsons1
1University of Liverpool,2The Countess of Chester Hospital

Ensartinib inhibits ABC drug efflux transporters and biotransformation enzymes and modulates pharmacokinetic multidrug resistance in vitro

Year:

Session type:

Dimitrios Vagiannis1,Martin Svoren1,Frantisek Staud1,Martina Ceckova1,Jakub Hofman1
1Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology

T Cells engineered to express the IL-13Rα2 specific CAR and a PD-L1 specific switch receptor show increased anti-tumor activity in the Glioblastoma tumor microenvironment

Year:

Session type:

Abel De Castro1,Abel De Castro1,Grant Wilson1,Megan Keys1,Jonathan Arroyo1
1Azusa Pacific University